SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rise is being tied mainly to Morgan Stanley naming it a top pick, with traders highlighting AWS growth and AI opportunities such as Trainium, Bedrock and agentic commerce. Many are bullish on the rally, while others question whether it will last and point to heavy AI spending and uncertain returns as risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep slide toward fresh lows, with bearish traders citing possible continued dilution, upcoming filings, and doubts about Truth Socials engagement and business prospects. Political backlash over Trumps policies and midterm prospects dominates the broader debate, while some traders view the decline as a buying opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention amid a sharp selloff as competing wet-AMD trial results shake confidence in retinal TKI therapies and raise questions about AXPAXLIs differentiation and commercial prospects. Traders disagree on whether competitor setbacks and Oculars positive SOL-1 results strengthen its position or whether lingering clinical and regulatory uncertainty outweighs its planned NDA filing.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is under pressure amid repeated analyst price-target cuts tied to soft residential roofing demand, a prolonged housing recovery, and higher costs, extending a steep slide toward new lows. Traders are divided between frustration over the selloff and managements limited communication, and long-term optimism about the acquisition strategy and eventual integration gains.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, addressing the FDAs earlier efficacy concerns; the company plans to resubmit its application. Traders are broadly positive on the results but debate the remaining regulatory path and dizziness reports, while others point to profit-taking and possible short-covering as the stock trades volatile.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent insider share purchases by the CEO and directors have fueled hopes of a rebound, with traders watching for a sustained move above a key technical level. Skeptics point to weakness in the core Celsius brand and say speculation about a Pepsi buyout is unconfirmed.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after an earnings-driven rally, with traders pointing to a return to profitability and strong year-over-year revenue growth amid demand for InP substrates used in AI data-center optics. Bulls see room for growth, while skeptics argue the valuation is stretched and the stock remains highly volatile.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and repeated underperformance versus Bitcoin are driving attention, with traders pointing to doubts about its AI/data-center pivot and the lack of signed tenant leases alongside criticism of management and shareholder dilution. Some are buying the sharp dip or anticipating a short squeeze, but bearish traders see continued downside absent a contract or stronger Bitcoin-linked gains.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

XERSs sharp rally and breakout above its prior high are fueling takeover speculation, especially chatter about Lundbeck and a possible bidding war, though no deal is confirmed and some traders doubt the rumors. Others point to revenue growth and the XP-8121 pipeline as support for the companys prospects independent of a sale.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its quarterly results, with traders focused on margins and profitability despite strong deliveries; bullish bets on the recent rally and an earnings move contrast with bearish expectations of a miss. The Roadster reveal has also fueled speculative SpaceX-merger chatter, though traders disagree about its business significance and whether a deal is likely.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Big Money, Bold Science, and Next Wave of Biotech Catalysts

Biotechnology is delivering a fresh wave of developments that could reshape investor expectations for Disc Medicine (NASDAQ:IRON), Silence Therapeutics (NASDAQ:SLN), NeOnc Technologies Holdings (NASDAQ:NTHI), and Alaunos Therapeutics (NASDAQ:TCRT).

Futures Rise As Dip Buyers Rush Back Into Chips After Worst Nasdaq Week Since Liberation Day

Futures Rise As Dip Buyers Rush Back Into Chips After Worst Nasdaq Week Since Liberation Day

 US futures are higher - but well off session highs hit before the European open - as dip buyers storm back into chipmakers after the Nasdaq's worst week since the April 2025 tariff turmoil...

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion.
DataMEDS AI (NASDAQ:MEDS) shares moved upwards byread more...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPR NewswireNEW YORK, Oct. 2, 2026NEW YORK, Oct. 2, 2026...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPR NewswireNEW YORK, Sept. 21, 2026 NEW YORK, Sept. 21, 2026...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRONPR...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONPR NewswireNEW YORK, Sept. 11, 2026 NEW YORK, Sept. 11, 2026...

Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones

Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hematocrit in polycythemia vera patients.read more...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON PR Newswire NEW YORK, Aug. 26, 2026 NEW YORK, Aug. 26, 2026...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON PR Newswire NEW YORK, Aug. 17, 2026 NEW YORK, Aug. 17, 2026...

Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The agency said that the company must provide evidence of clinical benefit from “adequate and well-controlled trial(s)” for approval.</li><li>Disc Medicine’s bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program.&nbsp;</li><li>Disc said it would resubmit its application following the completion of its APOLLO trial and expects a fresh decision from the agency by mid-2027.</li></ul>Shares of Disc Medicine (IRON) slumped 21% on Friday after the U.S. Food and Drug Administration refused to approve the company’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria.Disc Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">FDA’s Rationale</h2>The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit. The agency said that the company must now provide evidence of clinical benefit from “adequate and well-controlled trial(s)” for approval.The agency also expressed willingness to meet with the company to discuss options including the completion of an ongoing late-stage trial called Apollo and using it to seek a traditional approval.Disc Medicine was seeking approval of the pill in Erythropoietic Protoporphyria, a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-receives-complete-response-letter-fda-bitopertin">confirmed</a> the receipt of the letter and said that it expects to seek a meeting with the agency.“The CRL will delay the potential approval of bitopertin, but we have confidence in the ongoing APOLLO trial…,” CEO John Quisel said. The company also added that the issues raised by the FDA in the letter are “readily addressable” with data from its APOLLO trial expected in the fourth quarter (Q4).The company said it would resubmit its application following the completion of the APOLLO trial and expects a fresh decision from the agency by mid-2027.Last month, Reuters reported that the FDA has delayed the review of bitopertin after its scientists flagged safety and efficacy concerns. The decision was previously slated for January-end but pushed back two weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user now expects the FDA to decide on an approval for the pills only by late 2027. “Debating whether to start a small position now or wait for further downside,” they wrote.<stembedurl>https://www.stocktwits.com/jamonda/message/644968897</stembedurl><a href="https://stocktwits.com/symbol/IRON">IRON stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-cease-one-time-sale-of-fsd-starting-sunday/cZRdcaLR4t0">Tesla To Cease One-Time Sale Of FSD In Favor Of Subscription Model</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

The stock surged following positive results from the APOLLO Phase 3 trial for bitopertin, which met all co-primary endpoints.

Traders are closely monitoring heavy short interest and institutional ownership, speculating on potential aggressive upward price action.

Investors are focused on the long-term outlook following the recent trial results, with plans for an NDA resubmission expected by late 2026.

Current Price	$79.62
Prev Close	$56.84
Open	$72.96
Dividend Yield	0.00%
50-Day Moving Average	$71.51
Beta	1.15
Avg. Volume	558,246.59
PE Ratio	-8.64

52-Week High	$99.50
52-Week Low	$40.00
Market Capitalization	$2.18B
EPS (Annual)	-$6.01
Price to Book	3.38
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IRON Fundamentals